Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
MWN-AI** Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reported its financial results for the three and twelve months ending December 31, 2025, showcasing significant growth, particularly in its flagship product, LUPKYNIS. The company achieved total revenues of $77.1 million for Q4 and $283.1 million for the full year, marking increases of 29% and 20%, respectively, compared to the previous year. LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis, generated $74.2 million in net product sales for Q4 and $271.3 million for the full year—an increase of 29% and 25% year-over-year.
Despite a decrease in collaboration and royalty revenue, largely due to prior-year milestone payments from its partner Otsuka, Aurinia saw net income soar to $210.8 million in Q4, up from just $1.4 million in 2024, and $287.2 million for the full year, rising sharply from $5.8 million the previous year. Earnings per share also reflected this strong performance, landing at $1.53 for Q4 and $2.07 for the full year.
Aurinia maintained a robust cash position, with $398.0 million available as of December 31, 2025. The company repurchased 12.2 million shares during the year for $98.2 million, signaling confidence in its long-term value.
Looking ahead, Aurinia projects total revenue for 2026 between $315 million and $325 million, driven by continued growth in LUPKYNIS adoption and the advancement of its promising pipeline candidate, aritinercept. The company expressed optimism for the upcoming year, focusing on expanding treatment options for autoimmune diseases. A conference call detailing these results was held on February 26, 2026.
MWN-AI** Analysis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) demonstrated a robust financial performance for the year ended December 31, 2025, marked by notable growth in total revenue and net product sales driven by its flagship product, LUPKYNIS. The company reported total revenues of $283.1 million, a 20% increase year-over-year, alongside a significant 25% increase in LUPKYNIS sales, underscoring the strong demand for this FDA-approved treatment for lupus nephritis.
The upward trajectory of sales is supported by Aurinia's guidance for 2026, projecting revenue in the range of $315 million to $325 million, which indicates a further growth rate of 11% to 15%. This guidance reflects strategic initiatives aimed at increasing the adoption of LUPKYNIS among patients. Investors should take note of the potential for this growth as Aurinia's current focus remains on expanding its market presence and advancing its pipeline, particularly with the dual inhibitor aritinercept set to enter further clinical trials.
Moreover, the company reported a remarkable net income of $210.8 million, primarily attributed to a significant income tax benefit relating to its deferred tax assets. While this net income figure appears inflated due to the tax benefit, the underlying operational performance shows a substantial increase in earnings before tax, indicating strong operational efficiency.
Given the promising sales trajectory and the strategic direction highlighted by management, Aurinia presents a compelling investment opportunity in the biopharmaceutical sector. However, investors should remain aware of the risks inherent in drug development, regulatory hurdles, and market competition. Maintaining a diversified portfolio and monitoring ongoing clinical developments will be crucial for potential investors considering Aurinia's stocks as a viable addition in 2026 and beyond.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Full Year 2025 LUPKYNIS Sales Grew 25%
Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress.
Financial Results
- Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024.
- Net Product Sales: For the three and twelve months ended December 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million, respectively, for the same periods of 2024.
- License, Collaboration and Royalty Revenue: For the three and twelve months ended December 31, 2025, license, collaboration and royalty revenue, which includes manufacturing services, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $2.9 million and $11.7 million, up 26% and down 38%, respectively, compared to $2.3 million and $18.9 million, respectively, for the same periods of 2024. The twelve months ended December 31, 2024 included a milestone payment of $10.0 million associated with LUPKYNIS regulatory approval in Japan.
- Net Income: For the three and twelve months ended December 31, 2025, net income was $210.8 million and $287.2 million, up 14957% and 4852%, respectively, compared to $1.4 million and $5.8 million, respectively, for the same periods of 2024. For the three and twelve months ended December 31, 2025, the Company recorded an income tax benefit of $175.1 million and $173.0 million, respectively, primarily due to the release of its valuation allowance on deferred tax assets that the Company now expects to realize. For the three and twelve months ended December 31, 2025, net income before income taxes was $35.7 million and $114.2 million, up 2875% and 1443%, respectively, compared to $1.2 million and $7.4 million, respectively, for the same periods of 2024.
- Diluted Earnings per Share: For the three and twelve months ended December 31, 2025, diluted earnings per share was $1.53 and $2.07, up 15200% and 5075%, respectively, compared to $0.01 and $0.04, respectively, for the same periods of 2024.
- Cash Flows from Operating Activities: For the three and twelve months ended December 31, 2025, cash flows from operating activities were $45.7 million and $135.7 million, up 52% and 206%, respectively, compared to $30.1 million and $44.4 million, respectively, for the same periods of 2024.
Cash Position
As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $398.0 million, compared to $358.5 million at December 31, 2024. For the year ended December 31, 2025, the Company repurchased 12.2 million of its common shares for $98.2 million.
2026 Total Revenue and Net Product Sales Guidance
For 2026, Aurinia expects total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.
“We are pleased to have delivered strong LUPKYNIS sales growth in 2025,” stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. “We expect 2026 to be an exciting year for Aurinia. We remain focused on increasing LUPKYNIS adoption among lupus nephritis patients and advancing aritinercept, a dual BAFF/APRIL inhibitor, which has the potential to treat a wide range of autoimmune diseases. We have initiated a clinical study of aritinercept in one autoimmune disease and plan to initiate a clinical study in an additional autoimmune disease in the first half of 2026.”
Webcast & Conference Call Details
A webcast and conference call will be hosted today, February 26th, at 8:30 a.m. ET. The link to the audio webcast is available here . To join the conference call, please dial 877-407-8029/+1 201-689-8029. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar , and on Aurinia’s website at www.auriniapharma.com .
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS (in thousands) | ||||||||
December 31, 2025 | December 31, 2024 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash, cash equivalents and restricted cash | $ | 80,213 | $ | 83,433 | ||||
Short-term investments | 317,784 | 275,043 | ||||||
Accounts receivable, net | 41,454 | 36,544 | ||||||
Inventory | 45,690 | 39,228 | ||||||
Prepaid expenses and deposits | 5,746 | 11,219 | ||||||
Other current assets | 1,080 | 1,129 | ||||||
Total current assets | 491,967 | 446,596 | ||||||
Deferred tax assets, net | 176,194 | — | ||||||
Finance right-of-use lease assets | 73,865 | 92,072 | ||||||
Intangible assets, net | 3,761 | 4,355 | ||||||
Operating right-of-use lease assets | 3,596 | 4,068 | ||||||
Property and equipment, net | 2,111 | 2,731 | ||||||
Other noncurrent assets | 93 | 823 | ||||||
Total assets | $ | 751,587 | $ | 550,645 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,313 | $ | 5,187 | ||||
Accrued expenses | 66,621 | 64,971 | ||||||
Finance lease liabilities, current portion | 16,523 | 14,046 | ||||||
Deferred revenue | 3,720 | 11,002 | ||||||
Operating lease liabilities, current portion | 1,067 | 1,026 | ||||||
Other current liabilities | 2,480 | 1,531 | ||||||
Total current liabilities | 93,724 | 97,763 | ||||||
Finance lease liabilities, less current portion | 52,322 | 58,554 | ||||||
Deferred revenue, less current portion | 12,648 | 1,699 | ||||||
Deferred compensation and other noncurrent liabilities | 6,662 | 9,408 | ||||||
Operating lease liabilities, less current portion | 4,900 | 5,743 | ||||||
Total liabilities | 170,256 | 173,167 | ||||||
Shareholders' equity | ||||||||
Common shares - no par value, Unlimited shares authorized, 132,323 and 140,883 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,120,035 | 1,187,696 | ||||||
Additional paid-in capital | 111,263 | 126,999 | ||||||
Accumulated other comprehensive loss | (599 | ) | (647 | ) | ||||
Accumulated deficit | (649,368 | ) | (936,570 | ) | ||||
Total shareholders' equity | 581,331 | 377,478 | ||||||
Total liabilities and shareholders’ equity | $ | 751,587 | $ | 550,645 | ||||
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) | ||||||||||||||||
Three months ended | Years ended | |||||||||||||||
December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | |||||||||||||
(unaudited) | ||||||||||||||||
Revenue | ||||||||||||||||
Net product sales | $ | 74,173 | $ | 57,582 | $ | 271,345 | $ | 216,186 | ||||||||
License, collaboration and royalty revenue | 2,941 | 2,285 | 11,710 | 18,947 | ||||||||||||
Total revenue | 77,114 | 59,867 | 283,055 | 235,133 | ||||||||||||
Operating expenses | ||||||||||||||||
Cost of revenue | 8,799 | 5,552 | 32,665 | 28,248 | ||||||||||||
Selling, general and administrative | 29,255 | 37,032 | 101,794 | 172,028 | ||||||||||||
Research and development | 10,895 | 8,107 | 32,505 | 20,785 | ||||||||||||
Restructuring | — | 15,351 | 1,647 | 23,106 | ||||||||||||
Other (income) expense, net | (5,074 | ) | (4,506 | ) | 9,530 | (4,347 | ) | |||||||||
Total operating expenses | 43,875 | 61,536 | 178,141 | 239,820 | ||||||||||||
Income (loss) from operations | 33,239 | (1,669 | ) | 104,914 | (4,687 | ) | ||||||||||
Interest income | 3,498 | 3,988 | 13,573 | 16,970 | ||||||||||||
Interest expense | (1,047 | ) | (1,146 | ) | (4,330 | ) | (4,835 | ) | ||||||||
Net income before income taxes | 35,690 | 1,173 | 114,157 | 7,448 | ||||||||||||
Income tax (benefit) expense | (175,104 | ) | (256 | ) | (173,045 | ) | 1,696 | |||||||||
Net income | $ | 210,794 | $ | 1,429 | $ | 287,202 | $ | 5,752 | ||||||||
Earnings per share | ||||||||||||||||
Basic | $ | 1.60 | $ | 0.01 | $ | 2.14 | $ | 0.04 | ||||||||
Diluted | $ | 1.53 | $ | 0.01 | $ | 2.07 | $ | 0.04 | ||||||||
Shares used in computing earnings per share | ||||||||||||||||
Basic | 131,942 | 142,179 | 134,367 | 143,057 | ||||||||||||
Diluted | 138,160 | 147,675 | 138,700 | 146,194 | ||||||||||||
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) | ||||||||||||
Years ended December 31, | ||||||||||||
2025 | 2024 | 2023 | ||||||||||
Cash flows from operating activities: | ||||||||||||
Net income (loss) | $ | 287,202 | $ | 5,752 | $ | (78,020 | ) | |||||
Adjustments to reconcile consolidated net income (loss) to cash flows from operating activities: | ||||||||||||
Deferred income tax benefit | (176,194 | ) | — | — | ||||||||
Amortization and depreciation | 19,449 | 19,445 | 11,647 | |||||||||
Share-based compensation | 14,678 | 31,596 | 45,311 | |||||||||
Foreign exchange loss (gain) on revaluation of Monoplant finance lease liability | 9,685 | (5,910 | ) | 5,949 | ||||||||
Net amortization of premiums and discounts on investments | (10,179 | ) | (12,731 | ) | (12,141 | ) | ||||||
Non-cash write-down of inventory | — | — | 916 | |||||||||
Other, net | (200 | ) | 788 | (1,515 | ) | |||||||
Net changes in operating assets and liabilities: | ||||||||||||
Accounts receivable, net | (4,910 | ) | (12,455 | ) | (10,606 | ) | ||||||
Inventory | (6,462 | ) | 477 | (15,869 | ) | |||||||
Prepaid expenses and other current assets | 5,522 | (1,834 | ) | 4,399 | ||||||||
Other noncurrent operating assets | 730 | 31 | (16 | ) | ||||||||
Accounts payable | (1,874 | ) | 860 | 1,240 | ||||||||
Accrued expenses and other liabilities | (4,655 | ) | 13,330 | 12,154 | ||||||||
Deferred revenue | 3,668 | 5,789 | 3,763 | |||||||||
Operating lease liabilities | (802 | ) | (750 | ) | (673 | ) | ||||||
Cash flows from operating activities | 135,658 | 44,388 | (33,461 | ) | ||||||||
Cash flows from investing activities: | ||||||||||||
Proceeds from the sale and maturities of investments | 494,134 | 585,418 | 529,376 | |||||||||
Purchases of investments | (526,650 | ) | (545,832 | ) | (523,500 | ) | ||||||
Upfront lease payments | — | (43 | ) | (11,864 | ) | |||||||
Purchases of property, equipment and intangible assets | (252 | ) | (281 | ) | (718 | ) | ||||||
Cash flows from investing activities | (32,768 | ) | 39,262 | (6,706 | ) | |||||||
Cash flows from financing activities: | ||||||||||||
Repurchase of common shares | (98,156 | ) | (40,239 | ) | — | |||||||
Principal portion of finance lease payments | (13,136 | ) | (11,989 | ) | (10,025 | ) | ||||||
Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs and performance awards | 14,190 | 8,186 | 5,324 | |||||||||
Proceeds from issuance of common shares under ESPP | 756 | 1,084 | 1,850 | |||||||||
Taxes paid related to net settlement of exercises of stock options and vesting of RSUs and performance awards | (9,764 | ) | (6,134 | ) | (2,279 | ) | ||||||
Cash flows from financing activities | (106,110 | ) | (49,092 | ) | (5,130 | ) | ||||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (3,220 | ) | 34,558 | (45,297 | ) | |||||||
Cash, cash equivalents and restricted cash, beginning of the period | 83,433 | 48,875 | 94,172 | |||||||||
Cash, cash equivalents and restricted cash, end of the period | $ | 80,213 | $ | 83,433 | $ | 48,875 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226395307/en/
General Investor Inquiries
ir@auriniapharma.com
FAQ**
How does Aurinia Pharmaceuticals Inc (AUPH) plan to sustain the impressive sales growth of LUPKYNIS in the highly competitive market for autoimmune treatments in 2026 and beyond?
With the significant increase in net income for Aurinia Pharmaceuticals Inc (AUPH), what are the key strategies being implemented to maintain profitability in future quarters?
Given the planned clinical studies for aritinercept, how does Aurinia Pharmaceuticals Inc (AUPH) view the potential impact of this drug on its overall product pipeline and revenue forecasts?
How will Aurinia Pharmaceuticals Inc (AUPH) address potential risks and uncertainties highlighted in the forward-looking statements, especially concerning LUPKYNIS sales and clinical study results?
**MWN-AI FAQ is based on asking OpenAI questions about Aurinia Pharmaceuticals Inc (NASDAQ: AUPH).
NASDAQ: AUPH
AUPH Trading
0.96% G/L:
$14.16 Last:
276,807 Volume:
$14.24 Open:
